Past Event Information

San Diego 2018

Private equity is providing the M&A fuel for contract development and manufacturing organizations (CDMOs), fill-and-finish specialists, and clinical and commercial packaging partners

Regulation 'Round The World: How To Navigate International Outsourcing | Philadelphia 2018

It’s unanimous across this panel of international biopharma outsourcing experts: global playing fields are uneven, the players unequal, and supply-chain risks imbalanced.

New Business Models With CDMOs Include Better Pricing | Boston 2018

Edwin Beale has provided drug development and manufacturing services to biopharma companies for over 20 years. He’s heard it all when it comes to negotiating contracts between biopharma and CDMOs.

Lowering Risk To Your Physical Supply Chain | Boston 2018

Your supply chain – raw materials and intermediates, APIs and particularly commercial products – is at serious risk from bad actors. We are talking about falsified or stolen materials, counterfeiting, gray-market diversion, and other nefarious behaviors.  

2018

Outsourced Pharma conference season: Boston, Philadelphia, San Diego, San Francisco … here we come. Time for you to lead and learn among others in the industry, with the goal of making outsourcing more productive for your organization.

Aligning Motivations For Sponsor And Supplier Innovations | San Francisco 2017

Hard truths offset by soft skills make up the outsourced drug development and manufacturing industry.

San Diego 2017

CMOs were listening to biotech and pharma executives at Outsourced Pharma San Diego 2017. Those executives, in turn, were hearing out their service providers. From the many best practices and insights both sides offered, I’ve picked two to bring to you today. Let’s title them, “In The Line Of Sight,” and “Do Incentives Talk?”

Learning to fly: How to support incremental innovative solutions | Boston 2017

The Summit on Modern Day Drug Development and Manufacturing Outsourcing (Outsourced Pharma Boston, April 26-27) purposely led off with a session on incremental – or small “i” – innovation. That’s not because we were looking for “baby steps” to ease into tougher discussions. In fact, the mission was to kick-start us into advanced contemplations between drug sponsors and service providers.

Boston 2017

Paraphrasing Henry Hoppe, a long-time veteran of Sanofi Genzyme, and currently Vice President, Drug Development, Xenetic Bioscience: Companies on the bleeding edge of innovative technology in drug development and manufacturing should treat visits to the FDA more like Socratic dialogues than stressful duels.

Learning to Fly: How to Support Incremental Innovative Solutions | Boston 2017

We’re told that in the ranks of drug companies, more often than not, individuals wait for the “culture” to descend from the highest levels of the organization to miraculously instill the mindset that they can be innovative, and won’t be faulted if at times they come up short.

Boston 2017

Working at a contract drug development and manufacturing organization years ago, I had direct reports stationed around the globe. Among the lessons learned: There’s an industry-related conference somewhere on practically every day of the year.

2017

There are new leaders on the Outsourced Pharma Editorial Advisory Board. They’re not hesitant to provide bold analysis on outsourcing drug development and manufacturing.

San Francisco 2016

Outsourced Pharma brings drug owners together with their contract development and manufacturing organizations (CMOs), and other external partners. We discuss the disciplines and challenges of tech transfer and project management; processes, platforms and scale ups (and downs); reliability, quality and regulatory compliance; partner selection and measurement; costs and models for outsourcing; risk assessment and mitigation; customers and patients.

Technology in the supply chain | San Diego 2016

Among the edifying panels at this summer’s Outsourced Pharma San Diego, the one featuring Pfizer’s Bernie Huyghe – Technology in the supply chain – might have gained a conference apogee. The objective was to gain insight into an overriding question: How do we inject more innovation and technology into Pharma’s external drug development and manufacturing supply chain?

Conference Preview | San Francisco 2016

It is an era of innovation in an age of outsourcing. We are fortunate to reside in this flourishing industry now riding the tide of the times. And the supply chain, to add even more adventure, is becoming Pharma’s super hero of innovation. But like any super hero, the drug development and manufacturing supply chain struggles with a dual identity.

Top 10 quality/regulatory topics for your outsourcing | San Diego 2016

Five experts go undercover to prioritize a secret top-ten list of quality topics for Pharma and Bio sponsors selecting contract development and manufacturing organizations (CMOs). After weeks of discussion, they select a conference venue with a room chockfull of drug industry sponsors and service providers to unveil their work.

Real pricing and value in outsourcing | San Diego 2016

“What we’re doing up here is never done – focusing on that one input in public.” So says the serious moderator of the opening panel at Outsourced Pharma San Diego. “Instead of focusing on money, you talk openly about ‘value,’” he continues. “Well, what is that? Or it’s all about ‘relationships.’ The industry talks partnership in public, but behind closed doors, aren’t prices and costs closing or breaking outsourcing business deals?”

Boston 2016

I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. In common is a partiality to sharing strategies and best practices with anybody who’ll listen. These people have come to believe in a camaraderie of industry; a rising tide lifts all boats.

Boston 2016

“Most of the CMOs we spoke to, frankly, just thought we were crazy.” -- comment from a biopharma executive at Outsourced Pharma Boston 2016. Crazy, that is, like a fox. And this sponsor found an equally crafty contract development and manufacturing organization willing to join its pursuit in developing a new class of medicines. Today, that sponsor-provider relationship exemplifies a new model of alliance between emerging biopharma and CMOs.

Boston To Bangalore: Where in the world do I find my outsourcing partner? | Boston 2016

Am I starting an article on biopharma outsourcing by noting Frederick Engels, co-author (with Karl Marx) of The Communist Manifesto (1848)? Only to point this out: from collectivism to capitalism and its resultant open markets (Adam Smith wrote The Wealth of Nations in 1776), much thought has been devoted to the concept of product “value.” Like with Engels, the notion has mostly been boiled down to a fundamental equation: value = cost/price plus profit.

Shire's Approach: The "golden rule" in outsourcing partnerships | Boston 2016

How do biopharmaceutical companies handle CMO and supplier relationships that stem from M&A activity? In reply, one might recall the old refrain, “Very carefully.” Actually, with a healthy dose of nuance, that’s not far from accurate. Who better to provide that nuance than Shire? The folks there know M&A and outsourcing as well as anyone in the global biopharma industry today. For them, CMO integration, management and assessment traverses three dimensions: quality, process and supply performance.